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Dear Dr. Kittisupamongkol,
Thank you for your response to our paper.
In our study, we analyzed the risk of falling and
orthostatic hypotension in glaucoma patients and not the
prescription habits of ophthalmologists. Therefore, we
cannot state that ophthalmologists are not likely to
prescribe beta-blockers to glaucoma patients with cardio-
vascular disorders or symptoms suggesting cardiovascular
disease. However, at least in the Netherlands, there seems
to be a trend towards a change of the first-line IOP-
lowering drugs to the newer generation medications,
especially the prostaglandins. This may partly be caused
by the huge promotion by the pharmaceutical industry, who
put a lot of money into the development of these newer
drugs. In addition, several case-reports have been published
recently emphasizing the possible cardiovascular side-
effects of the ophthalmic beta-blocker [1–3].
As a response, we wanted to show that the ‘old’ beta-
blocker still is a good, safe, and effective drug in IOP lowering
in the ophthalmic practice. As mentioned in your comments,
the change in guidelines for use of beta-blockers also supports
that the beta-blocker is still not an outdated drug.
IOP lowering might not be the only way to ‘treat’
glaucoma, and in the future, new treatment possibilities
hopefully will be discovered. The fact that IOP lowering is
now for decades the only proven way of ‘treating’
glaucoma suggests that this belongs to the 50% of
knowledge that has not shown to be wrong.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
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